|
XBiotech
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases. History XBiotech was founded in 2005 in Vancouver, Canada by John Simard. The company moved its headquarters to Austin, Texas in 2008. In September 2016, XBiotech was listed on Nasdaq, raising $70.9 million through its initial public offering (IPO). The company allocated about $42 million of the proceeds to complete later-stage trials for one of its key cancer drugs and to construct a new manufacturing and research facility in southeast Austin. The remaining funds were used for earlier-stage trials of other products and general corporate purposes. In March 2017, XBiotech announced a registered direct offering in which it sold over $30 million of its common shares at a price of $13 per share. In the same year, XBiotech opened a 40,000 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Janssen Pharmaceutical
Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceuticals was purchased by New Jersey–based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), later renamed to Janssen Research and Development, LLC (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company. Subsidiaries * Actelion * Cilag AG * Janssen Biotech (formerly ''Centocor'') * Janssen Vaccines (formerly ''Crucell'') * Tibot ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Xilonix
Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). , bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the Colon (anatomy), colon or rectum (parts of the large intestine). Signs and symptoms may include Lower gastrointestinal ... and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis. Bermekimab is being developed by XBiotech Inc. References Antibodies Monoclonal antibodies for tumors {{antineoplastic-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
